Drug Trial Radar · NCT07752394
Penpulimab Combined With Chemotherapy for Patients With Locally Advanced Hypopharyngeal Carcinoma
Last checked: Nov 19, 2026Latest source record: Aug 7, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
15
Planned (sponsor's estimate)
Start
Aug 23, 2026
Primary completion
Aug 23, 2031
Study completion Aug 23, 2031
Sponsor
- Lead sponsor
- Tang-Du HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 7, 2026
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a prospective, single-arm, phase II clinical study aimed to evaluate the efficacy and safety of penpulimab combined with chemotherapy in the treatment of locally advanced hypopharyngeal carcinoma.
Conditions
- Head & Neck Cancer
Interventions
FinotonlimabDrug
Finotonlimab was administered by intravenous infusion at a dose of 200 mg,d1, Q3W,for 2-4 cycles Other Name:
Nab-paclitaxelDrug
treatment Regimen:Nab-paclitaxel was administered by intravenous infusion at a dose of 260mg/m² ,d1, Q3W,for 2-4 cycles
carboplatinDrug
treatment Regimen: Carboplatin dosage was calculated using the Calvert formula (dose = target AUC × \[GFR + 25\]), d1,IV,Q3W,for 2-4 cycles
Primary outcomes
What the sponsor says the trial is designed to measure.
- Major pathological response rate (MPR)Time frame: [Time Frame: Within 1-2 week after radical surgery (performed 2-3 weeks after the completion of 2 cycles of neoadjuvant treatment)]
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Tangdu Hospital, Air Force Medical University, Xi'an 710038, Shaanxi Province, China
Xi’an, Shanxi, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.